<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="453">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00571155</url>
  </required_header>
  <id_info>
    <org_study_id>HELLO-Study 2007</org_study_id>
    <secondary_id>EudraCT Number: 2007-005063-96</secondary_id>
    <nct_id>NCT00571155</nct_id>
  </id_info>
  <brief_title>Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery</brief_title>
  <official_title>Prospective Trial of Intravenous Levetiracetam in Patients With Primary Brain Tumors and at Least One Symptomatic Seizure Who Undergo Biopsy or Cytoreductive Surgery (HELLO-study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the feasibility, efficacy and safety of
      intravenous and oral antiepileptic treatment with levetiracetam in patients with primary
      brain tumors and symptomatic epilepsy in the period of neurosurgical intervention.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Feasibility of standardized treatment of patients with primary brain tumors and symptomatic epilepsy with levetiracetam in the period of neurosurgical intervention.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy, safety and tolerance of intravenous and oral levetiracetam in patients with primary brain tumors and symptomatic epilepsy in the period of neurosurgical intervention.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Primary Brain Tumor</condition>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levetiracetam</intervention_name>
    <description>oral and intravenous dosing 2000-3000 mg per day</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age ≥ 18 years

          -  suspected primary brain tumor by imaging

          -  planned bioptical or cytoreductive surgery of the tumor

          -  symptomatic epilepsy

          -  Karnofsky performance score ≥ 70%

          -  women with child bearing potential must perform sufficient contraception

          -  sufficient haematologic, hepatic and renal function by laboratory testing

        Exclusion Criteria:

          -  treatment with other antiepileptic drugs other than levetiracetam in the last seven
             days before surgery

          -  known allergic reaction to levetiracetam or other serious side effects

          -  known, not tumor-induced, epilepsy

          -  previous brain surgery

          -  dementia

          -  participation in another clinical trial

          -  addiction to drugs or alcohol

          -  pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Weller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University-Hospital of Tuebingen, Department of General Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Tuebingen, Department of General Neurology</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <lastchanged_date>August 19, 2009</lastchanged_date>
  <firstreceived_date>December 10, 2007</firstreceived_date>
  <responsible_party>
    <name_title>Prof. Michael Weller</name_title>
    <organization>University Hospital Tuebingen, Department of General Neurology</organization>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etiracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
